XTalks

MARCH 3, 2021

BridgeBio is dedicated to developing therapies for genetic diseases with unmet needs. BridgeBio said in an announcement that the novel therapy was developed based on “BridgeBio’s commitment to developing a treatment for MoCD Type A in collaboration with the experts and families in the MoCD Type A community.”

FDA Approval 64

FDA Approval Genotype Clinical Trials Clinical Trials 64

XTalks

MARCH 1, 2024

This day acts as an opportune moment for professionals in healthcare, life sciences and related fields to highlight the importance of HPV prevention and vaccination as well as the recent advancements in screening and treatment.

Vaccination 52

Vaccination Vaccine Life Science FDA Approval 52

XTalks

JANUARY 22, 2021

Taiwan-based health and biotech company MedFluid has developed a rapid automated bacterial identification screening tool that can also tailor antibiotic treatments to an infection. It identifies bacteria using both genotypic and phenotypic assessments within 1.5

Bacteria 52

Bacteria In-Vitro Genotype Marketing 52

XTalks

NOVEMBER 10, 2020

” A rare disease diagnosis can also influence family planning options, as well as lead to better development tools, support for patients, and improved patient outcomes. We work with our users and collaborators internationally to develop these systems. ” or “Why is my child different?”

Genome 98

Genome Genomics Medicine Genetic Disease 98

XTalks

DECEMBER 12, 2023

This is crucial not only for understanding these conditions but also for developing targeted therapeutic strategies. To accurately identify these genetic factors, genotyping techniques such as Sanger sequencing, next-generation sequencing (NGS) and copy number variant analysis are used.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

FEBRUARY 4, 2021

Data generated through high-throughput omics approaches paired with clinical patient records can give rise to remarkably robust datasets to inform and guide disease insights and development of targeted therapeutics. Genomic biomarker discovery helps drive the development of innovative new personalized therapies. Biobanking Models.

Research 98

Research Biobanking Drugs Genome 98

XTalks

APRIL 24, 2023

To achieve this, Medpace works in multi-disciplinary teams of experts to jointly develop and execute advanced therapy protocols. For rare disease studies where there is little or no clinical trial experience, outcome assessments would have to be validated within a clinical development program.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

pharmaphorum

FEBRUARY 17, 2022

Identified as the “VB variant,” the virus has proved to be highly virulent and to speed up the progression of a patient developing AIDS faster. Therefore, the risk of developing AIDS more rapidly was higher. Unfortunately, individuals with the VB variant had viral loads between 3.5 Effects of the variant. About the author.

Genome 98

Genome Genomics Genetics Genotype 98

XTalks

MARCH 26, 2025

South San Francisco-based biotech Kezar Life Sciences (NASDAQ: KZR) announced topline results from its Phase IIa PORTOLA trial evaluating zetomipzomib for the treatment of autoimmune hepatitis (AIH). Attendees will learn how clinical trial assays and genotyping kits can enhance research and clinical insight.

Trials 66

Trials Life Science Clinical Trials Clinical Trials 66